Announcements Trials

Browse Landscape

Phase

Phase 1 4 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Recurrence 4 Multiple Myeloma 4 Lymphoma 4 Ovarian Neoplasms 3 Burkitt Lymphoma 3 Neoplasms, Plasma Cell 2 Nasopharyngeal Carcinoma 2 Lymphoma, T-Cell 2 Leukemia, Myeloid, Acute 2 Solid Tumors 1 Solid Tumor 1 Solid Cancer 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1 POEMS Syndrome 1 Neuromyelitis Optica 1 Neuroblastoma 1 Neoplasms, Neuroepithelial 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myositis 1 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1 Myasthenia Gravis 1 Multiple Sclerosis 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Lymphoma, Mantle-Cell 1

Interventions

Oncolytic Virotherapy 2 fluoromisonidazole 1 fludarabine 1 aldesleukin 1 adavosertib 1 Radiotherapy, Intensity-Modulated 1 Magnetic Resonance Spectroscopy 1 Luteolin 1 Interleukin-2 1 Fluorodeoxyglucose F18 1 Cyclophosphamide 1 Clinical Protocols 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Carcinoma × fludarabine × Clear all

NCT05141474 2024-11-07

NEXTGENTIL-ACT

Vall d'Hebron Institute of Oncology

Phase EARLY_PHASE1 Recruiting

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡